Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific
E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in
combination with chemotherapy to treat Chinese relapsed/refractory AML patients.